Tiantan Biological: Recombinant human coagulation factor complex completes Phase III clinical trials.

Tian Tan Biotechnology announced on December 4th that the "Human Prothrombin Complex" developed by its subsidiary Guizhou Biological Pharmaceutical Co., Ltd. of China National Pharmaceutical Group has completed Phase III clinical trials and obtained a summary report of the clinical trials. The clinical trial results of Human Prothrombin Complex show that after infusion, it can significantly increase the levels of coagulation factors II/VII/IX/X in patients with hemophilia B, improve the coagulation function of patients with hemophilia B, alleviate bleeding symptoms and signs, and has good efficacy for patients with hemophilia B. At the same time, safety analysis results show that the drug has good safety for patients with hemophilia B during clinical application.